CRISPR start-up Synthego raises $41 million

Bone cell therapy company Bone Therapeutics receives 2.3 million in funding from the Wallonian Government.

Celyad commences THINK trial with its cell-based CAR-T/NKR-2 immunotherapy 

Ablynx will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday 12 January, at 1.30 am CET (Wednesday 11 January 2017 at 4:30 p.m. PST).

Call for research grants by Fund Alphonse & Jean Forton, managed by the King Baudouin Foundation, and Belgian Cystic Fibrosis Association.

Some of the biggest CRISPR-using companies have created an IP-sharing alliance on their technology. CRISPR Therapeutics, Intellia, Caribou Biosciences and ERS Genomics have banded together in an effort to protect their IP as a team. The companies rely on patents held by UC Berkley, Emmanuelle Charpentier (one of the main pioneers in the CRISPR field) and the University of Vienna.

After being the first European university to receive the GMP (Good Manufacturing Practices) certification for the quality control of drugs in 2014, ULg is now also the first university in the world to be prequalified by the WHO (World Health Organization). 

GPCR drug designer Confo Therapeutics has announced that John Berriman was appointed as Chairman of the Board. Berriman is a known biotech veteran and has served on the boards of many biotech companies, including stem cell play ReNeuron and immunotherapeutics specialist Autolus. Most notably, Berriman was Chairman of Heptares Therapeutics, another company exclusively focused on GPCR drug development. Berriman’s insight and experience in the GPCR space will no doubt be most valuable to Confo.